The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients.
The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients.
复制标题
HER1和HER2的生存与表达之间的关系取决于Her3和Her4的表达：对膀胱癌患者的研究。
DOI：
10.1038/sj.bjc.6603154
复制
发表时间：
2006-06-05
影响因子：
8.8
通讯作者：
Nexo, E
中科院分区：
文献类型：
--
作者：
Memon, A A;Sorensen, B S;Meldgaard, P;Fokdal, L;Thykjaer, T;Nexo, E
表皮生长因子 (EGF) 受体 HER1 和 HER2 表达增加与大多数研究的癌症预后不良有关。最近，EGF 系统剩余的两种受体 HER3 和 HER4 的高表达与良好的预后有关。然而，HER1和HER2受体在膀胱癌中的预后意义存在争议，并且这些受体的不同组合的表达对患者生存的影响尚不清楚。因此，我们通过实时聚合酶链反应检测了 88 名膀胱癌患者活检组织中所有四种 EGF 受体的 mRNA 表达，随访中位生存期为 38.5 个月（范围 1-117 个月）。 HER1 和 HER2 的单独表达与生存率没有相关性。然而，与HER1高表达和HER3和HER4低表达相比，HER1高表达和HER3和HER4高表达与更好的预后相关(P=0.0006)。此外，与表达高 HER2 但表达低 HER3 和 HER4 的肿瘤患者的生存期相比，在高 HER2 与高 HER3 和 HER4 共表达的患者中观察到生存期显着更长（P=0.0005）。我们的结果表明，HER1 和 HER2 高表达肿瘤患者的最终结果取决于 HER3 和 HER4 的表达。
Increased expression of the epidermal growth factor (EGF) receptors, HER1 and HER2 are related to poor prognosis in most cancers studied. Recently, a high expression of the two remaining receptors of the EGF system, HER3 and HER4 has been related to a favourable prognosis. However, prognostic significance of HER1 and HER2 receptors in bladder cancer is controversial and the effect of the expression of different combinations of these receptors on patient survival is not well understood. Therefore, we examined the mRNA expression of all four EGF receptors with real-time polymerase chain reaction in biopsies from 88 patients with bladder cancer, where the survival was followed for a median of 38.5 months (range 1–117 months). Expression of HER1 and HER2 alone showed no correlation with survival. However, a high expression of HER1 together with high expression of HER3 and HER4 correlated to a better prognosis compared to the high expression of HER1 together with low expression of HER3 and HER4 (P=0.0006). Also, a significantly longer survival was observed in patients expressing high HER2 when coexpressed with high HER3 and HER4, as compared to the survival in patients with tumours expressing high HER2 but low HER3 and HER4 (P=0.0005). Our results suggest that the final outcome of patients with high HER1- and HER2-expressing tumours depends on the expression of HER3 and HER4.